Research

Hormonal

GLP-1 receptor agonists (GLP-1 RAs) are displacing bariatric surgery as the primary obesity treatment in the US, evidenced by a 1451% increase in GLP-1 RA use and a 65% decline in bariatric surgery procedures.

GLP-1 medications are becoming the dominant obesity treatment in the US, largely replacing bariatric surgery in utilization trends. However, surgery remains a crucial option for severe obesity due to its durability, especially if GLP-1 medications are discontinued. Patients should discuss long-term adherence and potential side effects with their providers.

GoodSupportsHIGH confidence
This population-based analysis in the United States highlights a significant shift in obesity treatment, marked by a 65% reduction in bariatric surgery, accompanied by a 14-fold increase in the utilisation of GLP-1 RAs.
Ghadeer K. Dawwas et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Large retrospective cohort study using national claims data (MarketScan IBM) covering 2011-2022, though observational and subject to confounding.

Source

Shifting obesity treatment paradigms: Trends of glucagon‐like peptide‐1 receptor agonists and bariatric surgery in the United States

Ghadeer K. Dawwas et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16600

cohort · n=299755Cited 4×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →